Over the past decade, compelling evidence demonstrated that constitutive activation of NF-κB and aberrant regulation of the signaling pathways that control its activity are involved in cancer development and progression, as well as in resistance to therapy in many types of malignancies including GBM [3–6]. This evidence concerns the gene NFKB1 and cancer.